Spores from two distinct colony types of the strain Bacillus subtilis PB6 substantiate anti-inflammatory probiotic effects in mice

Clinical Nutrition

Volumn 31, Issue 6, 2012, Pages 987-994

  Foligné, Benoît ^a,b,c,d   Peys, Eric ^e   Vandenkerckhove, Jan ^e   Van hemel, Johan ^e   Dewulf, Joëlle ^a,b,c,d   Breton, Jérôme ^a,b,c,d   Pot, Bruno ^a,b,c,d  

^a INSERM U1019   (France)

^b UNIV LILLE   (France)

^c CNRS   (France)

^d INSERM   (France)

^e Kemin Industries Inc   (United States)

Author keywords

Anti inflammatory; Bacillus; Immunomodulation; Probiotics; Spores; TNBS mice model

Indexed keywords

ANABAN; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; MYELOPEROXIDASE; PREDNISOLONE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACILLUS SUBTILIS; BACTERIAL SPORE; BACTERIAL STRAIN; COLITIS; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BACILLUS SUBTILIS; BODY WEIGHT; CELL LINE; COLITIS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MICE; NEUTROPHILS; PROBIOTICS; SERUM AMYLOID A PROTEIN; SPORES, BACTERIAL; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84870292013     PISSN: 02615614     EISSN: 15321983     Source Type: Journal    
DOI: 10.1016/j.clnu.2012.05.016     Document Type: Article

References (65)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
2. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521.
3. Food and Agriculture Organization of the United Nations, World Health Organization Guidelines for evaluation of probiotic in food 2002.
4. Ruseler-van Embden J.G., Schouten W.R., van Lieshout L.M. Pouchitis: result of microbial imbalance?. Gut 1994, 35:658-664.
5. Gionchetti P., Rizzello F., Venturi A., Brigidi P., Matteuzzi D., Bazzocchi G., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
6. Kuisma J., Mentula S., Jarvinen H., Kahri A., Saxelin M., Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
7. Gosselink M.P., Schouten W.R., van Lieshout L.M., Hop W.C., Laman J.D., Ruseler-van Embden J.G. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
8. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
9. Gionchetti P., Rizzello F., Morselli C., Poggioli G., Tambasco R., Calabrese C., et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007, 50:2075-2082.
10. Mallon P.T., McKay D., Kirk S.J., Gardiner K. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, 4. Art.No.:CD005573. 10.1002/14651858.CD005573.pub2.
11. Hong H.A., Duc le H., Cutting S.M. The use of bacterial spore formers as probiotics. FEMS Microbiol Rev 2005, 29:813-835.
12. Sorokulova I.B., Pinchuk I.V., Denayrolles M., Osipova I.G., Huang J.M., Cutting S.M., et al. The safety of two Bacillus probiotic strains for human use. Dig Dis Sci 2008, 53:954-963.
13. Cutting S.M. Bacillus probiotics. Food Microbiol 2011, 28:214-220.
14. Selvam R., Maheswari P., Kavitha P., Ravichandran M., Sas B., Ramchand C.N. Effect of Bacillus subtilis PB6, a natural probiotic on colon mucosal inflammation and plasma cytokines levels in inflammatory bowel disease. Indian J Biochem Bio 2009, 46:79-85.
15. Im E., Choi Y.J., Pothoulakis C., Rhee S.H. Bacillus polyfermenticus ameliorates colonic inflammation by promoting cytoprotective effects in colitic mice. J Nutr 2009, 139:1848-1854.
16. Sorokulova I. Preclinical testing in the development of probiotics: a regulatory perspective with Bacillus strains as an example. Clin Infect Dis 2008, 46(Suppl. 2):S92-S95.
17. Endres J.R., Qureshi I., Farber T., Hauswirth J., Hirka G., Pasics I., et al. One-year chronic oral toxicity with combined reproduction toxicity study of a novel probiotic, Bacillus coagulans, as a food ingredient. Food Chem Toxicol 2011, 49:1174-1182.
18. Mileti E., Matteoli G., Iliev I.D., Rescigno M. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 2009, 4:e7056.
19. Preising J., Philippe D., Gleinser M., Wei H., Blum S., Eikmanns B.J., et al. Selection of bifidobacteria based on adhesion and anti-inflammatory capacity in vitro for amelioration of murine colitis. Appl Environ Microbiol 2010, 76:3048-3051.
20. López P., Gueimonde M., Margolles A., Suárez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol 2010, 138:157-165.
21. Grimoud J., Durand H., de Souza S., Monsan P., Ouarné F., Theodorou V., et al. In vitro screening of probiotics and synbiotics according to anti-inflammatory and anti-proliferative effects. Int J Food Microbiol 2010, 144:42-50.
22. Pérez-Cano F.J., Dong H., Yaqoob P. In vitro immunomodulatory activity of Lactobacillus fermentum CECT5716 and Lactobacillus salivarius CECT5713: two probiotic strains isolated from human breast milk. Immunobiology 2010, 215:996-1004.
23. Helwig U., Lammers K.M., Rizzello F., Brigidi P., Rohleder V., Caramelli E., et al. Lactobacilli, bifidobacteria and E. coli nissle induce pro- and anti-inflammatory cytokines in peripheral blood mononuclear cells. World J Gastroenterol 2006, 12:5978-5986.
24. Foligne B., Nutten S., Grangette C., Dennin V., Goudercourt D., Poiret S., et al. Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 2007, 13:236-243.
25. Kekkonen R.A., Kajasto E., Miettinen M., Veckman V., Korpela R., Julkunen I. Probiotic Leuconostoc mesenteroides ssp. cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production. World J Gastroenterol 2008, 14:1192-1203.
26. Vissers Y.M., Snel J., Zuurendonk P.F., Smit B.A., Wichers H.J., Savelkoul H.F. Differential effects of Lactobacillus acidophilus and Lactobacillus plantarum strains on cytokine induction in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 2010, 59:60-70.
27. van Hemert S., Meijerink M., Molenaar D., Bron P.A., de Vos P., Kleerebezem M., et al. Identification of Lactobacillus plantarum genes modulating the cytokine response of human peripheral blood mononuclear cells. BMC Microbiol 2010, 10:art293.
28. Peran L., Sierra S., Comalada M., Lara-Villoslada F., Bailón E., Nieto A., et al. A comparative study of the preventative effects exerted by two probiotics, Lactobacillus reuteri and Lactobacillus fermentum, in the trinitrobenzenesulfonic acid model of rat colitis. Br J Nutr 2007, 97:96-103.
29. Kwon H.K., Lee C.G., So J.S., Chae C.S., Hwang J.S., Sahoo A., et al. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc Natl Acad Sci USA 2010, 107:2159-2164.
30. Foligné B., Dewulf J., Breton J., Claisse O., Lonvaud-Funel A., Pot B. Probiotic properties of non-conventional lactic acid bacteria: immunomodulation by Oenococcus oeni. Int J Food Microbiol 2010, 140:136-145.
31. Foligné B., Deutsch S.M., Breton J., Cousin F.J., Dewulf J., Samson M., et al. Promising immunomodulatory effects of selected strains of dairy propionibacteria as evidenced in vitro and in vivo. Appl Environ Microbiol 2010, 76:8259-8264.
32. Chun J., Bae K.S. Phylogenetic analysis of Bacillus subtilis and related taxa based on partial gyrA gene sequences. Antonie Van Leeuwenhoek 2000, 78:123-127.
33. Araujo R., Rodrigues A.G., Pina-Vaz C. A fast, practical and reproducible procedure for the standardization of the cell density of an Aspergillus suspension. J Med Microbiol 2004, 53:783-786.
34. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest 1968, 97:77-89.
35. Foligné B., Nutten S., Steidler L., Dennin V., Goudercourt D., Mercenier A., et al. Recommendations for improved use of the murine TNBS-induced colitis model in evaluating anti-inflammatory properties of lactic acid bacteria: technical and microbiological aspects. Dig Dis Sci 2006, 51:390-400.
36. Wallace J.L., MacNaughton W.K., Morris G.P., Beck P.L. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989, 96:29-36.
37. Ameho C.K., Adjei A.A., Harrison E.K., Takeshita K., Morioka T., Arakaki Y., et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997, 41:487-493.
38. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982, 78:206-209.
39. Foligné B., Dessein R., Marceau M., Poiret S., Chamaillard M., Pot B., et al. Prevention and treatment of colitis with lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein. Gastroenterology 2007, 133:862-874.
40. GrzeŚkowiak L., Isolauri E., Salminen S., Gueimonde M. Manufacturing process influences properties of probiotic bacteria. Br J Nutr 2011, 105:887-894.
41. Peys E., Varghese J., Suresh P., Vandenkerckhove J., Van Hemel J., Chaniyilparampu R.N., et al. Effects of Bacillus subtilis 'PB6' (ATCC - PTA 6737) on Clostridium difficile Associated Diarrhea (CDAD) and Inflammatory Bowel Disease (IBD) in Animal Models. Am J Infect Dis 2007, 3:254-265.
42. Huang J.M., La Ragione R.M., Nunez A., Cutting S.M. Immunostimulatory activity of Bacillus spores. FEMS Immunol Med Microbiol 2008, 53:195-203.
43. Park J.M., Ng V.H., Maeda S., Rest R.F., Karin M. Anthrolysin O and other gram-positive cytolysins are toll-like receptor 4 agonists. J Exp Med 2004, 200:1647-1655.
44. La Ragione R.M., Woodward M.J. Competitive exclusion by Bacillus subtilis spores of Salmonella enterica serotype Enteritidis and Clostridium perfringens in young chickens. Vet Microbiol 2003, 94:245-256.
45. D'Arienzo R., Maurano F., Mazzarella G., Luongo D., Stefanile R., Ricca E., et al. Bacillus subtilis spores reduce susceptibility to Citrobacter rodentium-mediated enteropathy in a mouse model. Res Microbiol 2006, 157:891-897.
46. Fitzpatrick L.R., Small J.S., Greene W.H., Karpa K.D., Keller D. Bacillus coagulans GBI-30 (BC30) improves indices of Clostridium difficile-induced colitis in mice. Gut Pathog 2011, 3:16.
47. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther 2006, 8(Suppl. 2):S2.
48. Ishihara and Hirano IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002, 2002(13):357-368.
49. Gabay Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006, 8(Suppl. 2):S3.
50. Castagliuolo I., Galeazza F., Ferrari S., Elli M., Brun P., Cavaggioni A., et al. Beneficial effect of auto-aggregating Lactobacillus crispatus on experimentally induced colitis in mice. FEMS Immunol Med Mic 2005, 43:197-204.
51. de Palencia P.F., Werning M.L., Sierra-Filardi E., Dueñas M.T., Irastorza A., Corbi A.L., et al. Appl Environ Microb 2009, 75:4887-4891.
52. Deutsch S.M., Parayre S., Bouchoux A., Guyomarc'h F., Dewulf J., Dols-Lafargue M., et al. Contribution of surface beta-glucan polysaccharide to physicochemical and immunomodulatory properties of Propionibacterium freudenreichii. Appl Environ Microb 2012, 78:1765-1775.
53. Fanning S., Hall L.J., Cronin M., Zomer A., MacSharry J., Goulding D., et al. Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. Proc Natl Acad Sci USA 2011, 109:2108-2113.
54. Sendi P., Johansson L., Dahesh S., Van Sorge N.M., Darenberg J., Norgren M., et al. Bacterial phenotype variants in group B streptococcal toxic shock syndrome. Emerg Infect Dis 2009, 15:223-232.
55. Henriques A.O., Moran C.P. Structure, assembly, and function of the spore surface layers. Annu Rev Microbiol 2007, 61:555-588.
56. Kailas L., Terry C., Abbott N., Taylor R., Mullin N., Tzokov S.B., et al. Surface architecture of endospores of the Bacillus cereus/anthracis/thuringiensis family at the subnanometer scale. Proc Natl Acad Sci USA 2011, 108:16014-16019.
57. Sánchez B., Arias S., Chaignepain S., Denayrolles M., Schmitter J.M., Bressollier P., et al. Identification of surface proteins involved in the adhesion of a probiotic Bacillus cereus strain to mucin and fibronectin. Microbiology 2009, 155:1708-1716.
58. Lebeer S., Vanderleyden J., De Keersmaecker S.C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev 2010, 8:171-184.
59. Fujiya M., Musch M.W., Nakagawa Y., Hu S., Alverdy J., Kohgo Y., et al. The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe 2007, 1:299-308.
60. Kim K., Jung S.Y., Lee D.K., Jung J.-K., Park J.K., Kim D.K., et al. Suppression of inflammatory responses by surfactin, a selective inhibitor of platelet cytosolic phospholipase A2. Biochem Pharmacol 1998, 55:975-985.
61. Hosoi T., Ametani A., Kiuchi K., Kaminogawa S. Improved growth and viability of lactobacilli in the presence of Bacillus subtilis (natto), catalase, or subtilisin. Can J Microbiol 2000, 46:892-897.
62. Rachmilewitz D., Katakura K., Karmeli F., Hayashi T., Reinus C., Rudensky B., et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004, 126:520-528.
63. Drouault-Holowacz S., Foligné B., Dennin V., Goudercourt D., Terpend K., Burckel A., et al. Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: in vitro and in vivo considerations. Clin Nutr 2006, 25:994-1003.
64. Gasson M.J. Plasmid complements of Streptococcus lactis NCDO 712 and other lactic streptococci after protoplast-induced curing. J Bacteriol 1983, 154:1-9.
65. Sambrook J.E., Fritsch F., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory, New York. 2nd ed.